We won’t stop: A message to the cystic fibrosis community
Vertex is committed to working alongside the CF community on this journey to support those living with CF.
Vertex is committed to working alongside the CF community on this journey to support those living with CF.
Learn how we support independent research in cystic fibrosis (CF) through our Vertex CF Research Innovation Awards and Vertex Innovation Awards programs.
Our commitment to the sickle cell community extends beyond our research. Learn how we’ve worked with Sickle Cell Warriors to amplify their voices and experiences, highlighting the multifaceted nature of this disease.
Congratulations to our newest Vertex Science Leaders Scholarship recipients.
Chief Scientific Officer David Altshuler reflects on the history of innovation that serves as inspiration as we pursue a brighter future for people living with type 1 diabetes.
Dr. Schneider joined our board in 2024, bringing more than two decades of experience in the health care industry as a physician, scientist and health care executive. She is the co-founder and Chief Executive Officer of Homeward Health, a company committed to rearchitecting the delivery of health and care for nearly 60 million Americans living in rural communities. Prior to co-founding Homeward Health in 2022, she served as President and Chief Medical Officer of Livongo Health, a biotechnology company serving people with chronic conditions, from 2015 to 2020, where she led the company through the largest consumer digital health Initial Public Offering in history and the industry’s largest merger between Livongo and Teladoc Health. She also served in multiple leadership roles at Castlight Health, a health care navigation company for self-insured companies, from 2010 to 2015, most recently as Chief Medical Officer. Dr. Schneider serves on the board of directors at Jasper Health and Maven Health. She was previously a member of the board of directors at two special purpose acquisition companies (SPACs): Revolution Healthcare Acquisition Corp. (from March 2021 to December 2022) and Health Assurance Acquisition Corp. (from September 2020 until it liquidated in November 2022). She has been honored by Modern Healthcare as one of the “100 Most Influential People in Healthcare” and by Fierce Healthcare as a “Woman of Influence” for her work empowering women and modeling diversity and inclusion in the workplace. Dr. Schneider holds a B.S. in biology from the College of the Holy Cross, an M.D. from Johns Hopkins University School of Medicine, and an M.S. in health services research from Stanford University.
Dr. Schneider joined our board in 2024, bringing more than two decades of experience in the health care industry as a physician, scientist and health care executive. She is the co-founder and Chief Executive Officer of Homeward Health, a company committed to rearchitecting the delivery of health and care for nearly 60 million Americans living in rural communities. Prior to co-founding Homeward Health in 2022, she served as President and Chief Medical Officer of Livongo Health, a biotechnology company serving people with chronic conditions, from 2015 to 2020, where she led the company through the largest consumer digital health Initial Public Offering in history and the industry’s largest merger between Livongo and Teladoc Health. She also served in multiple leadership roles at Castlight Health, a health care navigation company for self-insured companies, from 2010 to 2015, most recently as Chief Medical Officer. Dr. Schneider serves on the board of directors at Jasper Health and Maven Health. She was previously a member of the board of directors at two special purpose acquisition companies (SPACs): Revolution Healthcare Acquisition Corp. (from March 2021 to December 2022) and Health Assurance Acquisition Corp. (from September 2020 until it liquidated in November 2022). She has been honored by Modern Healthcare as one of the “100 Most Influential People in Healthcare” and by Fierce Healthcare as a “Woman of Influence” for her work empowering women and modeling diversity and inclusion in the workplace. Dr. Schneider holds a B.S. in biology from the College of the Holy Cross, an M.D. from Johns Hopkins University School of Medicine, and an M.S. in health services research from Stanford University.
At Vertex, we’re fearless in our pursuit of innovation, and we’ve spent over 20 years researching potential medicines to treat pain.
Dr. Ogo Egbuna leads clinical development for our genetic kidney disease programs. Learn more about APOL1-mediated kidney disease from a nephrologist’s perspective.
We are relentless in our quest to improve the lives of people living with serious diseases. Thanks to the dedication of teams led by Paul Negulescu, our medicines have profoundly impacted the cystic fibrosis community, earning recognition such as the prestigious Canada Gairdner International Award.
Kerri and Taylor Rhodes felt helpless as they watched their son struggle with substance use disorder after being prescribed an opioid to help with postoperative pain. When their daughter faced the same procedure years later, the family was determined to find a different way to manage her pain.